Fertility Preservation Iatrogenic denied as duplicate or overlapping therapy by Aetna?

Aetna's specific coverage criteria for FERTILITY PRESERVATION IATROGENIC are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Aetna Issues a Duplicate-Therapy Denial for Iatrogenic Fertility Preservation — and How to Appeal

Iatrogenic fertility preservation refers to egg, sperm, or embryo cryopreservation performed before a medical treatment — most commonly chemotherapy or radiation — that is expected to impair or eliminate reproductive capacity. Aetna may issue a duplicate-therapy denial when it determines that a preservation service billed in a given cycle overlaps with a service already authorized or previously billed, or when monitoring, medications, and retrieval are bundled inconsistently across claims. This is a billing-logic or administrative error rather than a clinical disagreement.

## Why This Denial Is Appealable

Duplicate-therapy denials in this context are typically administrative errors that resolve quickly on appeal when the patient and provider demonstrate that the billed services are clinically distinct — for example, that medications and retrieval represent a single coordinated treatment cycle rather than a duplication of a prior cycle. The clinical facts almost always distinguish the services, and a clear, organized appeal that maps each billed item to its unique clinical function is highly effective.

## Your Federal Appeal Rights

• Internal appeal: Under ERISA §503 (employer plans) or applicable state law, you are entitled to a full-and-fair internal review. File within the deadline on your EOB — commonly 180 days.
• External review: Under ACA §2719, once internal remedies are exhausted, you may request independent external review. The IRO's decision is binding on Aetna. Total window is approximately four months from denial. Expedited review (72-hour decision) is available when health is at serious risk or when the underlying cancer treatment cannot be safely delayed.

## Concrete Appeal Steps and Timeline

1. Obtain the full claim file and duplicate-therapy determination — confirm exactly which billed service Aetna considers duplicative, and of which prior claim. 2. Review all prior authorizations and paid claims with the provider's billing team to map out the complete billing history. 3. File internal appeal with documentation below, within the EOB deadline. 4. Escalate to external review if upheld.

## Documentation to Gather

• Itemized billing records: Line-by-line breakdown from the provider showing what was billed, on what dates, and for what service.
• Clinical treatment records: Physician notes and cycle records confirming each billed service is clinically distinct from any prior service.
• Prior authorization records: Any PA confirmations from Aetna, showing what was authorized and when.
• Provider billing clarification letter: The billing team and treating physician jointly attest that the billed items are not duplicates and explain the clinical sequence.
• Underlying oncology or treatment plan: Documents the medical necessity of each cycle or service in the context of the planned gonadotoxic treatment.

## Criteria-Mapping Structure

In your appeal letter, present a side-by-side table: the prior claim Aetna identified as a duplicate on the left; the denied claim on the right; and the clinical difference — different service date, different service type, or different clinical purpose — for each line. A structured response like this makes it impossible for the reviewer to sustain a duplicate finding without addressing each item individually.